Iovance Biotherapeutics, Inc. (IOVA) Net earnings per share growth forecast for next year

Symbol and logo of brand Iovance (IOVA)

Iovance Biotherapeutics (IOVA) is attracting top specialists thanks to its first FDA-approved product and extensive career advancement opportunities. The forward earnings per share growth forecast demonstrates the issuer's resilience, with the metric standing at 75.00. The asset is shielded from macroeconomic shocks by stable demand for biotechnology, while growth scales through the creation of joint infrastructure with leading oncology centers.

IOVA - Iovance Earnings growth forecast for next year over the range 07/04/2022 - 11/16/2026

Metric breakdowns and analytics for Iovance (IOVA)

- price and consensus price forecast:
Analysis of all company metrics:Iovance
Core merchandise of Iovance Biotherapeutics Inc

An analysis of the forward-looking EPS growth vector for Iovance Biotherapeutics (IOVA) reflects the consensus earnings forecast, where market expectations for business scaling clash with pragmatic calculations of future cash flows. This metric is sensitive to operational risks associated with CMO outsourcing and cellular material logistics, as any disruptions in the external contractor chain directly adjust the company's final profitability assessment.

Direct competitors

Net earnings per share growth forecast for next year immunitybio.com|Expected earnings per share growth for next year immunocore.com (IMCR)|Net earnings per share growth forecast for next year Janux Therapeutics Inc (JANX)|Expected earnings per share growth for next year Arcus Bio RCUS|Zymeworks Inc - Expected earnings per share growth for next year|Earnings growth forecast for next year Tango Therapeutics Corp TNGX|IMTX - Net earnings per share growth forecast for next year|XNCR (xencor.com) - Projected earnings per share growth rate for next year|Compass Therapeutics Corp (CMPX) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Replimune Corp (REPL)|Expected earnings per share growth for next year LYEL|IPHA - Net earnings per one share growth forecast for next year|Expected earnings per share growth for next year PYXS (Pyxis Oncology, Inc.)|Projected earnings per share increase next year CGEN|Earnings growth forecast for next year IOBT (IO Biotech)|Expected earnings per share trend next year STRO|minktherapeutics.com - Earnings growth forecast for next year|Expected net earnings per share growth next year Werewolf Therapeutics, Inc.|Immix (IMMX) - Net earnings per share growth forecast for next year|ALX Oncology Holdings - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Cue Biopharma|Earnings growth forecast for next year pdsbiotech.com|Net earnings per share growth forecast for next year sonnetbio.com (SONN)|MAIA: Net earnings per share change forecast for next year|Liminatus Pharma Inc. - Expected earnings per share growth for next year|LAVA Therapeutics N.V. (LVTX) - Expected net earnings per share growth next year|NXTC - Net earnings per share growth forecast for next year|LPTX: Net earnings per share growth forecast for next year|Intensity Therapeutics (INTS) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Sensei Bio (SNSE)|TOVX (Theriva Biologics Inc) - Earnings growth forecast for next year|Gritstone bio (GRTS) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year KA|Consensus forecast of earnings per share growth for next year NexImmune Inc|Net earnings per share growth forecast for next year turnstonebio.com TSBX|Consensus forecast of earnings per share growth for next year Vaccinex Inc (VCNX)|HARP - Net earnings per share growth forecast for next year